213 related articles for article (PubMed ID: 15115225)
1. New drugs in India over the past 15 years: analysis of trends.
Ghosh A; Hazra A; Mandal SC
Natl Med J India; 2004; 17(1):10-6. PubMed ID: 15115225
[TBL] [Abstract][Full Text] [Related]
2. The drug lag: new drug introductions in India in comparison to United States.
Karan RS; Malhotra S; Pandhi P
J Assoc Physicians India; 2002 Jun; 50():782-7. PubMed ID: 12240842
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
5. Trends in antimicrobial drug development: implications for the future.
Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
[TBL] [Abstract][Full Text] [Related]
6. The year's new drugs and biologics--2007.
Graul AI; Prous JR; Barrionuevo M; Bozzo J; Castaner R; Cruces E; Revel L; Rosa E; Serradell N; Sorbera LA
Drug News Perspect; 2008; 21(1):7-35. PubMed ID: 18301807
[TBL] [Abstract][Full Text] [Related]
7. The year's new drugs & biologics - 2008.
Graul AI; Revel L; Barrionuevo M; Cruces E; Rosa E; Verges C; Lupone B; Diaz N; Castaner R
Drug News Perspect; 2009; 22(1):7-29. PubMed ID: 19209296
[TBL] [Abstract][Full Text] [Related]
8. Financial anatomy of neuroscience research.
Dorsey ER; Vitticore P; De Roulet J; Thompson JP; Carrasco M; Johnston SC; Holloway RG; Moses H
Ann Neurol; 2006 Dec; 60(6):652-9. PubMed ID: 17192926
[TBL] [Abstract][Full Text] [Related]
9. Recent drug approvals from the US FDA and EMEA: what the future holds.
Pevarello P
Future Med Chem; 2009 Apr; 1(1):35-48. PubMed ID: 21426069
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009.
Kaitin KI; DiMasi JA
Clin Pharmacol Ther; 2011 Feb; 89(2):183-8. PubMed ID: 21191382
[TBL] [Abstract][Full Text] [Related]
11. Trends in development and approval times for new therapeutics in the United States.
Reichert JM
Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
[TBL] [Abstract][Full Text] [Related]
12. Measuring progress in neglected disease drug development.
Cohen JP; Sturgeon G; Cohen A
Clin Ther; 2014 Jul; 36(7):1037-42. PubMed ID: 24906971
[TBL] [Abstract][Full Text] [Related]
13. The year's new drugs and biologics--2006.
Graul AI; Sorbera LA; Bozzo J; Serradell N; Revel L; Prous JR
Drug News Perspect; 2007; 20(1):17-44. PubMed ID: 17332898
[TBL] [Abstract][Full Text] [Related]
14. Economics of new oncology drug development.
DiMasi JA; Grabowski HG
J Clin Oncol; 2007 Jan; 25(2):209-16. PubMed ID: 17210942
[TBL] [Abstract][Full Text] [Related]
15. Clinical development and review times for new drugs in Japan: associated factors.
Ishibashi T; Yasuda K; Kusama M; Sugiyama Y; Ono S
Clin Pharmacol Ther; 2010 Oct; 88(4):487-91. PubMed ID: 20739921
[TBL] [Abstract][Full Text] [Related]
16. A pilot study to build a database on seven anti-hypertensive drugs.
Fujita T; Miura Y; Mayama T
Pharmacoepidemiol Drug Saf; 2005 Jan; 14(1):41-6. PubMed ID: 15534857
[TBL] [Abstract][Full Text] [Related]
17. [Medical problems and risks of switching drugs according to legal requirements of drug discount contracts in Germany].
Pruszydlo MG; Quinzler R; Kaltschmidt J; Haefeli WE
Dtsch Med Wochenschr; 2008 Jul; 133(27):1423-8. PubMed ID: 18592450
[TBL] [Abstract][Full Text] [Related]
18. Pharma industry in India.
Sundaram VM
Drug News Perspect; 2008; 21(1):59-63. PubMed ID: 18301810
[TBL] [Abstract][Full Text] [Related]
19. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
[TBL] [Abstract][Full Text] [Related]
20. The economics of pediatric formulation development for off-patent drugs.
Milne CP; Bruss JB
Clin Ther; 2008 Nov; 30(11):2133-45. PubMed ID: 19108801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
